Rhythm Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Rhythm Pharmaceuticals (RYTM).

Price Target Range — 10 Quarters

Analyst Consensus — 18 Analysts

2S.Buy

15Buy

1Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$132Upside to Avg. PT+43.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$155→$159
Sep 14, 2026	Leerink Partners	—	Assumes	Outperform	$133
Aug 28, 2026	Deutsche Bank	David Hoang	Initiate	Hold	$120
Aug 7, 2026	JP Morgan	Priyanka Grover	PT Raise	Overweight	$145→$146
Aug 5, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$142→$143
Aug 5, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$141→$155
Aug 5, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$155→$160
Jul 27, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$145
Jul 7, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$137→$141
Jun 16, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$143→$151
Jun 15, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$144→$155
May 7, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$140→$143
May 6, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$136→$137
May 6, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$143→$144
Mar 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$100→$105
Mar 20, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$131→$142
Mar 20, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$139→$149
Mar 20, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$152→$155
Mar 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$110→$100
Mar 17, 2026	Citigroup	Samantha Semenkow	PT Cut	Buy	$136→$131

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $155 to $159.

Benzinga Newsdesk

PRO
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $141 to $155.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $155 to $160.

Benzinga Newsdesk

Rhythm Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Rhythm Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

PRO
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

PRO
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

PRO
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

PRO
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

People Also Watch

People Also Watch

Rhythm Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Rhythm Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

PRODeutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

PROJP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

PROCitigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

PRORBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

PROCitizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

PRO
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

PRO
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

PRO
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

PRO
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160